Incidence of Peripheral Neuropathy in Elderly Patients with Metastatic Breast Cancer Receiving Eribulin (Eri) or Ixabepilone (Ixa) Chemotherapy

被引:0
|
作者
Lee, L. [1 ]
Vahdat, L. [1 ]
机构
[1] Weill Cornell Med Coll, New York, NY USA
关键词
D O I
暂无
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
引用
收藏
页码:S176 / S177
页数:2
相关论文
共 50 条
  • [31] Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy
    Denison, U
    Baumann, J
    Peters-Engl, C
    Samonigg, H
    Krippl, P
    Lang, A
    Obermair, A
    Wagner, H
    Sevelda, P
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 79 (03) : 347 - 353
  • [32] Phase I/II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC)
    Schwartzberg, Lee S.
    Blakely, Laura J.
    Schnell, Frederick
    Christianson, David
    Andrews, Michael
    Johns, Amanda
    Walker, Mark
    CANCER RESEARCH, 2011, 71
  • [33] Evaluation of neuropathy in breast cancer patients treated with ixabepilone.
    Lee, JJ
    Low, JA
    Croarkin, E
    Parks, R
    Berman, AW
    Mannan, N
    Steinberg, SM
    Swain, SM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 42S - 42S
  • [34] Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
    Mehrotra, Shailly
    Sharma, Manish R.
    Gray, Elizabeth
    Wu, Kehua
    Barry, William T.
    Hudis, Clifford
    Winer, Eric P.
    Lyss, Alan P.
    Toppmeyer, Deborah L.
    Moreno-Aspitia, Alvaro
    Lad, Thomas E.
    Valasco, Mario
    Overmoyer, Beth
    Rugo, Hope
    Ratain, Mark J.
    Gobburu, Jogarao V.
    AAPS JOURNAL, 2017, 19 (05): : 1411 - 1423
  • [35] Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
    Pivot, X.
    Marme, F.
    Koenigsberg, R.
    Guo, M.
    Berrak, E.
    Wolfer, A.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1525 - 1531
  • [36] Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
    Shailly Mehrotra
    Manish R. Sharma
    Elizabeth Gray
    Kehua Wu
    William T. Barry
    Clifford Hudis
    Eric P. Winer
    Alan P. Lyss
    Deborah L. Toppmeyer
    Alvaro Moreno-Aspitia
    Thomas E. Lad
    Mario Valasco
    Beth Overmoyer
    Hope Rugo
    Mark J. Ratain
    Jogarao V. Gobburu
    The AAPS Journal, 2017, 19 : 1411 - 1423
  • [37] Diagnostic tools should be used for the diagnosis of chemotherapy induced peripheral neuropathy in breast cancer patients receiving taxanes
    van Haren, Frank
    van den Heuvel, Sandra
    Ligtenberg, Mandy
    Vissers, Kris
    Steegers, Monique
    CANCER REPORTS, 2022, 5 (10)
  • [38] Eribulin tolerability and correlation between neuropathy and a set of polymorphisms in metastatic breast cancer patients. Results from the PAINTER (Polymorphism And Incidence of Toxicity in ERibulin treatment) study
    La Verde, Nicla
    Damia, Giovanna
    Garrone, Ornella
    D'Onofrio, Loretta
    Fabi, Alessandra
    Ciccarese, Mariangela
    Generali, Daniele
    Nunzi, Martina
    Poletto, Elena
    Pedrazzoli, Paolo
    Cretella, Elisabetta
    Scandurra, Giuseppa
    Meattini, Icro
    Bertolini, Alessandro S.
    Cavanna, Luigi
    Romagnoli, Emanuela
    Legramandi, Lorenzo
    Guffanti, Federica
    Rulli, Eliana
    Moretti, Anna
    Bocci, Barbara
    Farina, Gabriella
    CANCER RESEARCH, 2020, 80 (04)
  • [39] The impact of whole-body vibration training on the incidence and the severity of chemotherapy-induced peripheral neuropathy in breast cancer patients receiving paclitaxel therapy
    Dalferth, Rebecca
    Hebbel, Hannah
    Sallach, Nadine
    Maass, Nicolai
    Letsch, Anne
    Schmidt, Thorsten
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 241 - 241
  • [40] Practical experiences with eribulin in patients with metastatic breast cancer
    Tesch, Hans
    Schneeweiss, Andreas
    ANTI-CANCER DRUGS, 2016, 27 (02) : 112 - 117